Trial Profile

A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of EIDD-2801 in hospitalized patients with COVID-19

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Molnupiravir (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Therapeutic Use

Most Recent Events

07 Jul 2020 According to a Ridgeback Biotherapeutics media release, it has started of enrollment in a Phase 2 trial of potential COVID-19 treatment EIDD-2801.Trial to be Conducted with the University of Liverpool, Liverpool School of Tropical Medicine & Southampton Clinical Trials Unit.
07 Jul 2020 Status changed from planning to recruiting, according to a Ridgeback Biotherapeutics media release.
25 Jun 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com